Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1360-1362
10.1182/blood-2022-160038